Specialized Biosimilar Focus Xbrane Biopharma’s expertise in developing high-demand biosimilars and long-acting injectables positions it as a key player in the affordable biosimilar market, creating opportunities to provide complementary manufacturing, formulation, or distribution services.
Recent Asset Sale The sale of research and development assets to Alvotech for approximately 28.9 million USD indicates a strategic shift towards commercialization, suggesting potential collaboration opportunities for partners looking to accelerate biosimilar approvals or market entry.
Funding and Investment Activity With recent short-term investments from Systematic Group amounting to 1.82 million USD, there is evidence of investor support and growth potential, making Xbrane a promising partner for joint ventures or co-development projects within biosimilars.
Product Innovation Launches The launch of biosimilars like Ximluci and the development of Nivolumab biosimilar demonstrate an active pipeline, offering potential sales opportunities in ophthalmology and oncology markets through distribution or licensing partnerships.
Market Expansion Potential Xbrane’s participation in European markets with biosimilars and strategic alliances reflects opportunities to collaborate on regional distribution, regulatory support, and market penetration efforts for biosimilar products.
Xbrane Biopharma AB uses 8 technology products and services including Microsoft 365, Font Awesome, TweenMax, and more. Explore Xbrane Biopharma AB's tech stack below.
| Xbrane Biopharma AB Email Formats | Percentage |
| First.Last@xbrane.com | 90% |
| First@xbrane.com | 10% |
Biotechnology ResearchStockholm, Sweden11-50 Employees
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.
Company Overview
Media & News
Funding & FinancialsXbrane Biopharma AB has raised a total of $1.8M of funding over 1 rounds. Their latest funding round was raised on Dec 02, 2024 in the amount of $1.8M.
Xbrane Biopharma AB's revenue is estimated to be in the range of $1M
Funding & FinancialsXbrane Biopharma AB has raised a total of $1.8M of funding over 1 rounds. Their latest funding round was raised on Dec 02, 2024 in the amount of $1.8M.
Xbrane Biopharma AB's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com